Industry news

05 January 2017

Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and  Trademark Office for U.S. Patent Application Number  15/086,485 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”

05 January 2017

Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Pierre Legault, MBA, CA, CPA to its board of directors.

04 January 2017

Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointment of  Richard L. Beckman , M.D. to the position of Chief Medical Officer.

03 January 2017

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its CNS-selective GABA_A modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).

Feel the Earth Move Under Your Brand?

Al Topin / Pharmaceutical Executive

It’s a new year with new forecasts, wise prognostications, and sage extrapolations informed by last year’s rear view mirror. They’re often insightful. Sometimes misguided. Always interesting.

Personalized Medicine Needs Personalized Marketing

Peter Houston / Pharmaceutical Executive

According to Grand View Research, the global personalized medicine market was valued at more than $1 billion in 2014 and is expected to reach almost $2.5 billion in 2022, a CAGR of 11.8 percent over the forecast period. 

Holding out for a pharma M&A rebound in 2017? It may be a while

Carly Helfand / FiercePharma

If there’s one word that describes 2016’s pharma M&A market, it’s “slow.” And while some industry watchers predict that the new year—and administration—could bring a jolt of energy to the dealmaking arena, no one’s expecting big changes fast.

With billions at stake, will biosims finally make a mark in the U.S. in 2017?

Eric Sagonowsky / FiercePharma

Biosimilars have already taken hold in Europe, with Celltrion's Remicade copy, for one, wreaking havoc on the branded med's sales. Whether they'll finally make their mark in the U.S., though, remains to be seen—and 2017 could be the year we find out.

2016's cybersecurity risks raise questions about future interconnectivity

Amirah Al Idrus / Fierce Medical Device

2016 saw a couple of incidents that spotlighted the vulnerability of medical devices to hacking and cyberattacks. But while cybersecurity flaws—such as those that could allow hackers to overdose a diabetic on insulin—can affect medical devices in their current form, the trend of increasing connectivity in med tech will only create more opportunities for unauthorized actors to exploit.

Artificial intelligence ramped up in 2016, but has to prove its utility in 2017

Amirah Al Idrus / Fierce Medical Device

According to MedyMatch Chief Financial Officer Michael Rosenberg, 2016 was a banner year for artificial intelligence. How does he know? “Even my mother knows what it is now. It’s going mainstream.”